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Loss of the epithelial phenotype and disruption of adhesion molecules is a hallmark in the epithelial–
mesenchymal transition (EMT) reported in several types of cancer. Most of the studies about the relevance of
adhesion and junction molecules in lung cancer have been performed using established tumors or in vitro
models. The sequential molecular events leading to EMT during lung cancer progression are still not well
understood. We have used a rat model for multistep lung carcinogenesis to study the status of adherens and
tight junction proteins and mesenchymal markers during EMT. After silica-induced chronic inflammation, rats
sequentially develop epithelial hyperplasia, preneoplastic lesions, and tumors such as adenocarcinomas and
squamous cell carcinomas. In comparison with normal and hyperplastic bronchiolar epithelium and with
hyperplastic alveolar type II cells, the expression levels of E-cadherin, a-catenin and b-catenin were significantly
reduced in adenomatoid preneoplastic lesions and in late tumors. The loss of E-cadherin in tumors
was associated with its promoter hypermethylation. a- and b-catenin dysregulation lead to cytoplasmic
accumulation in some carcinomas. No nuclear b-catenin localization was found at any stage of any pre-
neoplastic or neoplastic lesion. Zonula occludens protein-1 was markedly decreased in 66% of adenocarci-
nomas and in 100% squamous cell carcinomas. The mesenchymal-associated proteins N-cadherin and vimentin
were analyzed as markers for EMT. N-cadherin was de novo expressed in 32% of adenocarcinomas and 33% of
squamous cell carcinomas. Vimentin-positive tumor cells were found in 35% of adenocarcinomas and 88% of
squamous cell carcinomas. Mesenchymal markers were absent in precursor lesions, both hyperplastic and
adenomatoid. The present results show that silica-induced rat lung carcinogenesis is a good model to study
EMT in vivo, and also provide in vivo evidence suggesting that the changes in cell–cell adhesion molecules are
an early event in lung carcinogenesis, while EMT occurs at a later stage.
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Cell-to-cell and cell–matrix contacts, necessary for
proper epithelial tissue homeostasis and function,1
are mediated by multiprotein specialized structures
known as adherens and tight junctions. The basic
element of adherens junctions is the cadherin/
catenin complex, required for interaction between
neighboring cells. Tight junctions are formed by a
complex of transmembrane proteins, including
claudins and occludins, and other submembranous
cytoplasmic proteins such as zonula occludens
protein 1 (ZO-1).2 E-cadherin, the main cadherin
expressed in adherens junctions in normal epithelia,
belongs to a family of transmembrane glycoproteins
with a single spanning domain that mediates
calcium-dependent cell adhesion. E-cadherin repre-
sents a classical type I cadherin, and its short
intracellular tail binds to cytoplasmic proteins of
the catenin family, a, b and g, forming a link with
cytoskeletal actin filaments. This association with
the cytoskeleton deeply influences cell behavior and
motility through specific signaling molecules shut-
tling to the nucleus.3 In lung cancer, as in many
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other types of epithelial cancer, downregulation
of E-cadherin and other adherens junctions com-
ponents including a- and b-catenins has been
reported.4–6 Recently, it has been shown that repres-
sion of the E-cadherin gene in human primary
tumors is caused by aberrant hypermethylation of
its promoter.7
Nonepithelial cadherins have been found to be de
novo expressed in epithelial cancers in the course of
an epithelial to mesenchymal transition (EMT) that
has been described in epithelial carcinogenesis.8,9
EMT is a key mechanism during normal develop-
ment of multicellular organisms. During this pro-
cess, epithelial cells progressively acquire a
reversible or irreversible mesenchymal phenotype
that is essential for organogenesis.10 Morphogenetic
EMT is aberrantly recapitulated during tumorigen-
esis in a variety of epithelial cancers including
thyroid, liver, kidney, prostate, breast and lung.10,11
The common signature of this process involves
disruption of normal epithelial integrity, with loss
of morphological features of polarized epithelia, and
partial or total gain of mesenchymal markers with
progressive acquisition of a motile and invasive
phenotype.8 In addition to disrupted epithelial
morphology, dysregulation of adhesion and junc-
tional molecules and aberrant expression of
N-cadherin, EMT involves de novo expression of
other mesenchymal markers such as fibronectin and
vimentin in epithelial cells. N-cadherin, also a type I
cadherin, is not normally expressed in bronchoal-
veolar epithelium and is characteristic of nerve
cells, developing skeletal muscle, embryonic and
mature cardiac muscle cells, pleural mesothelial
cells and osteoblasts.12 It is also present in epithelial
tumor cells undergoing EMT.8,9 Fibronectin, vimen-
tin and other nonepithelial proteins have also been
found abnormally expressed in epithelial tumors.13–15
Vimentin is a class III intermediate filament widely
expressed during embryonic development in tissues
of mesenchymal origin.16 Its aberrant expression in
tumors and transformed cell lines has been corre-
lated with increased motility, invasive behavior
and poor prognosis.17,18 In lung, it is found in
fibroblasts, smooth muscle, endothelial and lym-
phoid cells, but it is not expressed in the normal
airway epithelial cells and there are no published
data on its expression during lung carcinogenesis.
Most of the studies about adhesion molecules and
EMT in neoplasia have been performed on in vitro
models, or on biopsies from fully established
invasive tumors. The multistep nature of the
events leading from a normal airway epithelial
tissue to a tumor has been proposed.19 Information
concerning the molecular events associated with
these progressive changes is still sparse and incom-
plete. For instance, sequential changes in the
expression of adherens and tight junction mole-
cules and mesenchymal markers have not been
investigated during multistep lung cancer progres-
sion. The alteration of adherens and tight junction
components and the development of EMT during
multistep carcinogenesis has not been reported so
far in an appropriate animal model, which could be
very useful to identify and validate markers of tumor
progression and invasion, and potential targets for
therapeutic intervention.
In the present study, we have used the silica-
induced rat model of multistep lung carcinogenesis,
which mimics many features observed in human
peripheral lung cancer.20–23 In this model, a single
intratracheal instillation of crystalline silica dust
suspended in saline leads to the appearance of
pulmonary silicosis and of proliferative epithelial
lesions with progressive severity, from alveolar and
bronchiolar epithelial hyperplasias to preneoplastic
adenomatoid lesions and to adenocarcinomas and
squamous cell carcinomas (See Materials and meth-
ods, Animal model). Adenocarcinomas were classi-
fied into fibrotic or nonfibrotic depending on the
degree of fibrosis present. In squamous cell carci-
nomas, two clearly distinguishable areas were found
namely: (a) well differentiated tumors with a central
area filled with keratin and (b) smaller irregular
solid cords of cells infiltrating into the adjacent
connective tissue, in some cases in direct contact
with the differentiated areas. We analyzed changes
in the expression of E-cadherin/a-catenin/b-catenin
proteins, ZO-1 tight junction protein, and the
mesenchymal markers N-cadherin and vimentin
during lung cancer progression. We observed mark-
edly reduced protein expression of E-cadherin,
a-catenin and b-catenin in tumors and preneoplastic
lesions. By contrast, reduction/absence of ZO-1 and
neoexpression of N-cadherin and vimentin were
only observed in tumors.
Materials and methods
Animal Model
Fisher F344/NCr female rats from Harlan UK
Limited (Oxon, UK) were employed. The crystalline
silica sample was 99% pure a-quartz (Min-U-Sil 5,
US Silica Co., Berkeley Springs, WV, USA), with
particle size less than 5mm.20,22 The silica sample
was suspended in sterile neutral buffered saline and
briefly sonicated to provide full dispersion. Rats at 8
weeks of age were anesthetized with a mixture of
oxygen and isofluorane, and placed on their backs
on a metal board slanted at a 601 angle with the
mouth kept open, and in this position, at the end of
an expiration, they received a single intratracheal
instillation of 16 mg quartz in 0.3 ml saline through a
7-cm-long, 19-gauge stainless steel blunt cannula,
bent at a 1401 angle near the top, connected to a
syringe.20 A total of 36 rats were instilled with 16 mg
quartz and the lungs obtained at months 1 (n¼ 5), 4
(n¼ 5), 11 (n¼ 2), 17 (n¼ 7) and 21 (n¼ 17) after
instillation. Several lesions were studied at these
time periods: hyperplasias of type II pneumocytes
(n¼ 27) beginning from month 1, hyperplasia of
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bronchiolar epithelial cells (n¼ 19) from month 4,
preneoplastic adenomatoid lesions (n¼ 28) from
month 8, and adenocarcinomas (n¼ 28) and squa-
mous cell carcinomas (n¼ 9) from month 11.
Hyperplastic and preneoplastic lesions were ob-
served not only at the time of appearance but also in
late stages. Tissues from control rats (n¼ 8), instilled
with 0.3 ml saline without quartz, were obtained at
months 6 (n¼ 4) and 12 (n¼ 4). The rats were
housed in specific pathogen-free conditions with
access to food and water ad libitum. Procedures
were carried out in strict compliance of the EU and
NIH relevant guidelines for use of laboratory
animals. The rats were killed by exsanguination
under anesthesia with Ketolars (Parke-Davis, Ma-
drid, Spain) and Rompu´ns (Bayer AG, Leverkusen,
Germany). The trachea was exposed by dissection
and ligated during maximal inspiration. The larynx,
trachea, bronchi, lungs, lymph nodes and heart were
removed ‘en bloc’ and fixed by immersion in 4%
formaldehyde in a 300 mOsm phosphate buffer for
24 h. Lung lobes were sectioned along their main
bronchial axis, embedded in paraffin, and sectioned
at 4-mm thickness. Paraffin-embedded lungs from
treated and control rats were used. Additional
specimens (n¼ 24) were obtained from previous
analogous experiments carried out at the National
Cancer Institute (NCI), Bethesda, MD.20,22
A subset of the late tumor was isolated from the
fresh unfixed lung and split into two parts. One of
the two halves was rapidly snap frozen in liquid
nitrogen and kept at 801C for DNA extraction. The
other half of the tumor was processed for histologi-
cal analysis. Normal lung from control rats was
processed in the same way.
Immunohistochemistry
Antibodies
For immunohistochemical analysis, the following
antibodies (Abs) tested for cross reactivity for
human and rat were used: anti-E-cadherin (C36)
(class, IgG2a mouse monoclonal) (BD Transduction
Laboratories, San Diego, CA, USA); anti-b-catenin
(E-5) (class, IgG1 mouse monoclonal; epitope,
residues 680–781 of b-catenin, human origin)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA);
anti-b-catenin (C14) (class, IgG1 mouse monoclonal)
(BD Transduction Laboratories, San Diego, CA,
USA); anti-a-catenin (class, IgG1 mouse monoclo-
nal) (Calbiochem, EMD Bioscience, Darmstadt,
Germany); anti-N-cadherin (3B9) (class, IgG1 mouse
monoclonal) (Zymed Laboratories, San Francisco,
CA, USA); anti-ZO-1 (class, Ig rabbit polyclonal;
epitope, residues 463–1109 of ZO-1, human
origin) (Zymed Laboratories, San Francisco, CA,
USA); anti-vimentin (V9) (class, IgG1 mouse mono-
clonal) (Dako, Barcelona, Spain); anti-cytokeratins
(MNF-116) (class, IgG1 mouse monoclonal) (Dako,
Barcelona, Spain).
Methods
For the immunohistochemical technique, the indir-
ect avidin–biotin-peroxidase method (Dako, Barce-
lona, Spain) was employed in the analysis of
E-cadherin, b-catenin, a-catenin and cytokeratins.
The EnVisions (K4001 and K4007; Dako) signal
enhancement system was used in the analysis of
N-cadherin, ZO-1 and vimentin. Slides were depar-
affined and incubated for 10 min with 3% H2O2 in
water to quench the endogenous peroxidase activity.
Heat-mediated antigen retrieval was used for anti-
bodies against E-cadherin, b-catenin, a-catenin,
N-cadherin and vimentin (microwave treatment,
15 min at 750 W and 15 min at 375 W) and an
enzymatic antigen retrieval method was employed
for antibodies against cytokeratins (7 min at 371C)
(protease type XIV, Sigma-Aldrich, Madrid, Spain),
and ZO-1 (12 min at 371C) (protease type XXIV,
Sigma-Aldrich, Madrid, Spain). Tissues were incu-
bated with 5% normal rabbit serum in Tris-buffered
saline (TBS) (Tris-HCl 0.05 M, 0.5 M NaCl,
PH¼ 7.36) for 30 min at room temperature. After
blotting the excess serum, the sections were incu-
bated with the primary antibody diluted in TBS at
41C overnight. Dilutions were: 1:50 for anti-
E-cadherin, a-catenin and ZO-1; 1:100 for anti-
b-catenin (E-5); 1:200 for anti-b-catenin (C-14),
N-cadherin, cytokeratins and vimentin. Tissues
were washed in TBS and incubated with the
appropriate secondary antibody. For the indirect
avidin–biotin-peroxidase method, biotinylated rab-
bit anti-mouse Ig antiserum was added at a 1:200
dilution for 30 min at room temperature, and after
washing, the slides were incubated 30 min at room
temperature with the avidin–biotin complex at a
1:100 dilution. In the EnVisions signal enhance-
ment system, the secondary monoclonal or poly-
clonal complex was used for 30 min at room
temperature. After washing the slides in TBS,
development of peroxidase with diaminobenzidine
and H2O2 was performed. After rinsing in water, the
sections were counterstained with Harris hema-
toxylin, dehydrated and mounted with distyrene,
plasticizer, xylene (DPX) mounting medium (BDH,
Poole, England).
Evaluation of immunostaining
Several histological types were analyzed in each
section, namely normal cells: normal bronchiole (B),
normal type II pneumocytes (TII Pn); hyperplastic
lesions: bronchiolar hyperplasia (BH) and type II
pneumocyte hyperplasia (TII PnH); preneoplastic
lesions: adenomatoid lesions (AL); and tumors:
adenocarcinoma (AC) and squamous cell carcinoma
(SCC).
To assess E-cadherin, b-catenin, a-catenin and ZO-
1 status quantitative evaluation of immunostained
sections was performed according to previously
published methods.24 Normal bronchioles present
in normal tissues or adjacent to the lesion were used
as internal control of staining. Staining intensity
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was graded as normal (value 3, intensity 475% of
the normal bronchiolar staining), low (value 2,
intensity 50–75% of the normal bronchiolar stain-
ing), very low (value 1, intensity 25–50% of the
normal bronchiolar staining) and no staining (value
0, intensity o25% of the normal bronchiolar
staining). The percentages of area were also assigned
from 100 to 0%. Multiplication of the intensity score
and the percentage area gave a final multiplication
value from 300 to 0. The multiplication values were
grouped into four immunoreactive scores defined
as ‘normal’ (multiplication values 300–201),
‘low’ (multiplication values 200–101), ‘very low’
(multiplication values 100–1) and ‘negative’ (multi-
plication value¼ 0). Scoring was carried out inde-
pendently by two independent observers with an
initial scoring agreement higher than 90%. Con-
sensus score was annotated for the discrepant
sections after joint review of these particular cases.
To analyze N-cadherin and vimentin status,
sections from each block were immunostained
for N-cadherin and vimentin. Normal bronchiolar
epithelial cells present in normal tissues or adjacent
to the lesion were used as internal control of
negative staining. Mesenchymal cells such as fibro-
blasts were used as internal controls. Number and
size of stained cell foci were recorded for each
section.
Statistical analysis
Statistical analysis was performed with the SPSS 9.0
software (SPSS Inc., Chicago, IL, USA). A Kruskal–
Wallis test was applied to the study of E-cadherin,
b-catenin and a-catenin. In the cases for which
significant statistical variations were present, com-
parison of preneoplastic and neoplastic epithelial
lesions with the corresponding normal bron-
chioles and hyperproliferative lesions was calcu-
lated using a Mann–Whitney U-test with the
Bonferroni adjustment. A Fisher exact test was
applied to the study of vimentin in fibrotic and
nonfibrotic adenocarcinomas.
Controls
Negative controls: Mouse IgG1 and IgG2a (Dako,
Barcelona, Spain) with specificity directed towards
Aspergillus niger glucose oxidase were used as
negative controls for immunohistochemical techni-
ques. Nuclear staining validation for E-5 and C-14
b-catenin antibodies: Human colon carcinoma sec-
tions were used to validate the nuclear staining of
b-catenin. Both of them stained the nuclei in the
control tumoral cells (data not shown).
Quantification of Global DNA Methylation
Genomic DNA was extracted from the frozen tumors
by conventional methods. The 5-methylcytosine
DNA content of rat lung tumors (adenocarcinomas,
n¼ 5; and squamous cell carcinomas, n¼ 4) and
control rat lungs (n¼ 6) was determined by high-
performance Capillary Electrophoresis (HPCE) as
previously described.25,26 Briefly, genomic DNA
(3–5 mg) was obtained from the different tissues
and DNA hydrolysis was carried out with 1.25 ml
(200 U/ml) of nuclease P1 for 16 h at 371C. Subse-
quently, alkaline phosphatase was added and mix-
tures were incubated for an additional 2 h at 371C.
Hydrolyzed samples were injected under pressure
(0.3 p.s.i.) for 3 s into an uncoated fused-silica
capillary in a CE system (P/ACTM MDQ, Beckman-
Coulter). Quantification of the relative methylation
of each DNA sample was determined as the
percentage of mC of total cytosines: mC peak
area 100/(C peak areaþmC peak area). All sam-
ples were analysed in duplicate and three analytical
measurements were made per replicate.
Bisulfite Genomic Analysis of the CDH1 CpG Island
DNA samples of five adenocarcinomas (Tumors 3, 4,
6, 8 and 9), four squamous cell carcinomas (Tumors
1, 2, 5, and 7) and six normal lungs (Normal 1–6)
were treated with sodium bisulfite as previously
described27 and primers (Figure 3c) spanning the
CpG island of the rat E-cadherin (CDH1) promoter
were used for bisulfite genomic sequencing.28 At
least six individual clones were sequenced for each
sample. A single CpG was considered to be
methylated (black dot) when more than half of the
clones retained an unmodified cytosine at that
position.
Results
First, we analyzed the expression of proteins
involved in cell-to-cell adhesion: E-cadherin,
b-catenin and a-catenin. Strong membranous stain-
ing for E-cadherin was found both in normal
bronchiolar epithelial cells (Figure 1a) and hyper-
plastic bronchiolar epithelium (Figure 1b), with no
statistical difference in the staining score. While
normal isolated type II pneumocytes showed very
low levels of E-cadherin (Figure 1c), hyperplastic
type II pneumocytes areas (n¼ 27) expressed sig-
nificantly higher amount of the protein, which was
also localized at the plasma membrane (Figure 1d).
In adenomatoid lesions (n¼ 28) (Figure 1e),
E-cadherin immunoreactivity was considerably re-
duced as compared to normal bronchiole and
hyperplastic lesions (Figure 2), Po0.001 compared
to normal bronchiole, bronchiolar hyperplasia and
type II pneumocyte hyperplasia. At the final time
point of the experiment (months 17–21) two differ-
ent tumor types were found: adenocarcinomas
(n¼ 28), which were more frequent, and squamous
cell carcinomas (n¼ 9). E-cadherin was significantly
reduced in both types of tumors (Figure 1f,g) as
compared to normal and hyperplastic bronchiolar
epithelium (Figure 2, Po0.001 for both comparisons).
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Figure 1 Immunohistochemistry of E-cadherin during silica-induced rat lung carcinogenesis. Expression in normal bronchiolar (a) and
alveolar (c) epithelium and in hyperplastic bronchiolar (b) and alveolar (d) epithelium. Very low expression in normal type II
pneumocytes (c) compared to hyperplastic type II pneumocytes (d) Inset: detail of the type II pneumocyte hyperplasia shown in (d) (e–g)
E-cadherin expression was decreased (arrowhead) in adenomatoid lesions (e), adenocarcinoma (f) and squamous cell carcinoma (g)
compared to normal (a) and hyperplastic (b) bronchiolar epithelium. Nuclear counterstain in all figures is with Harris hematoxylin.
Original magnifications:  120 (b,d–g);  300 (a,c,d inset). BrE: Bronchiolar epithelium.
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Moreover, E-cadherin was significantly reduced in
adenocarcinomas as compared to hyperplastic type
II pneumocytes (Figure 2, Po0.001). There was also
a reduction in E-cadherin expression in squamous
cell carcinomas as compared to hyperplastic type II
pneumocytes although it was not statistically sig-
nificant (Figure 2, NS).
The potential epigenetic regulation of gene ex-
pression in this model of multistage lung carcino-
genesis was first explored through the quantification
of the global DNA methylation levels of adenocarci-
nomas (n¼ 5) and squamous cell carcinomas (n¼ 4)
vs control lung tissues (n¼ 6) (Figure 3a). As it was
previously reported for human breast and colorectal
primary tumors,26 silica-induced carcinomas
showed a clear global genomic hypomethylation,
with an average loss of 25% of 5-methylcytosine
DNA content compared to the normal tissues. Next,
we determined the role of promoter hypermethyla-
tion in the transcriptional repression of the E-
cadherin gene in nine tumors and six saline instilled
control lungs (Figure 3d). We observed a CpG island
hypermethylation pattern in six of nine tumors
analyzed. Furthermore, we were able to study the
correlation between the E-cadherin protein expres-
sion and the promoter hypermethylation status in
Tumors 1–3. In these samples, direct bisulfite
sequencing analyses of the promoter region of
E-cadherin revealed a strong direct association
between E-cadherin promoter hypermethylation
(Figure 3d) and marked loss of E-cadherin protein
expression (Figure 3b) in Tumor 2 (squamous cell
carcinoma, Figure 1g) and Tumor 3 (adenocarcino-
ma, Figure 7a). However, Tumor 1 (squamous cell
carcinoma) showed normal E-cadherin expression
(Figure 3b) and its promoter region remained
unmethylated (Figure 3d).
The b-catenin expression profile was similar to E-
cadherin in normal tissues and in all lesions studied
(Figure 4a–h, and Figure 5). Strong membrane
staining of b-catenin was found in normal (Figure
4a) and hyperplastic (n¼ 19) (Figure 4b) bronchiolar
epithelium, and those levels were not statistically
different. Hyperplastic type II pneumocytes lesions
(n¼ 27) (Figure 4d) expressed significantly higher
levels of b-catenin compared to normal type II
pneumocytes (Figure 4c). Expression of b-catenin
was reduced in adenomatoid lesions (n¼ 28) (Figure
4e) compared to normal bronchiole and hyperplastic
lesions (Figure 5, Po0.001 compared to normal
bronchiole, bronchiolar hyperplasia and type II
pneumocyte hyperplasia). In adenocarcinomas
(n¼ 28) and squamous cell carcinomas (n¼ 9),
b-catenin was significantly reduced (Figure 4f,g)
compared to normal bronchiole and hyperplastic
lesions (Figure 5, Po0.001 compared to normal
bronchiole, bronchiolar hyperplasia and type II
pneumocyte hyperplasia). While adenomatoid le-
sions showed a membranous b-catenin staining
pattern, a noticeable cytoplasmic localization of this
protein was found in some of the tumors (Figure 4h).
Adenocarcinomas and squamous cell carcinomas
showed an exclusively granular cytoplasmic
b-catenin pattern in 15% of the tumors, whereas in
67% of the tumors, b-catenin was only localized at
the adherens junction complex of the plasma
membrane. The remaining tumors (18%) showed
both cytoplasmic and membrane localization. We
did not find nuclear localization, under our experi-
mental conditions, in any of the tumors studied,
including those with strong cytoplasmic b-catenin
expression.
a-catenin expression was always similar to E-
cadherin and b-catenin in normal tissues and the
lesions studied (data not shown). The mislocaliza-
tion pattern of a-catenin and b-catenin was found
simultaneously in the same cells when serial
sections of the tumors were analyzed.
We next studied ZO-1, a membrane-associated
component of tight junctions. Normal cells showed
submembranous localization at the apical region in
a button like appearance, whereas basal epithelial
cells showed no expression (Figure 6a, inset). Both
hyperplastic bronchiolar and alveolar epithelial
Figure 2 Statistical analysis of the expression of E-cadherin. Semiquantitative analysis of the expression of E-cadherin in the normal
epithelia and in the different types of lesions. Normal bronchiole adjacent to the lesion was used as internal positive control of staining
efficiency and as an internal standard for quantitation. Normal cells: normal bronchiole (B), normal type II pneumocytes (TII Pn);
hyperplastic lesions: bronchiolar hyperplasia (BH) and type II pneumocyte hyperplasia (TII PnH); preneoplastic lesions: adenomatoid
lesions (AL); and tumors: adenocarcinoma (AC) and squamous cell carcinoma (SCC). A Kruskal–Wallis test was applied and the post hoc
pairwise comparisons were calculated using a Mann–Whitney U-test with the Bonferroni adjustment.
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Figure 3 DNA methylation analysis in the normal epithelia and in tumors. (a) HPCE quantification of the global DNA methylation levels
in normal lung (n¼ 6) and in silica-induced adenocarcinomas (n¼ 5) and squamous cell carcinomas (n¼4). Results are expressed as
mean7s.d. (b) Multiplication values of the immunohistochemical signal as a measurement of the expression levels of E-cadherin in
normal and Tumor 1 (squamous cell carcinoma), Tumor 2 (squamous cell carcinoma) and Tumor 3 (adenocarcinoma) samples. Light gray:
normal E-cadherin protein expression; dark gray: low E-cadherin protein expression. (c) Bisulfite sequencing primers for the rat version
of the E-cadherin (CDH1) promoter. (d) Bisulfite genomic sequencing of the rat E-cadherin promoter in five adenocarcinomas (Tumors 3,
4, 6, 8 and 9), four squamous cell carcinomas (Tumors 1, 2, 5, and 7) and six normal lungs (Normal 1–6). At least six individual clones
were sequenced for each sample. The localization of the CpG island obtained with the NEWCPGREPORT software (EMBOSS; http://
mammoth.bii.a-star.edu.sg/emboss/index.html) is represented with a horizontal bar. The vertical bars represent the distribution of the
CpGs at the E-cadherin CpG islands and the vertical arrow indicated the transcriptional start point. Black dots indicate methylated CpGs
and white dots unmethylated. The position of the bisulfite sequencing primers used is represented with white horizontal arrows.
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cells showed similar levels of ZO-1. Loss of expres-
sion of ZO-1 was clearly observed in neoplastic
lesions compared to normal and hyperplastic
bronchiolar epithelium. In adenocarcinomas, 33%
expressed low ZO-1 levels and 66% showed
very low levels (Figure 6a). Every squamous cell
Figure 4 Immunohistochemistry of b-catenin during silica-induced rat lung carcinogenesis. Expression in normal bronchiolar (a) and
alveolar (c) epithelium and in hyperplastic bronchiolar (b) and alveolar (d) epithelium. Very low expression was found in normal type II
pneumocytes (c, inset) compared to hyperplastic type II pneumocytes (d, inset). (e–g) b-catenin expression was decreased (arrowhead) in
adenomatoid lesions (e), adenocarcinoma (f) and squamous cell carcinoma (g) compared to normal bronchiolar epithelium (a) and
hyperplastic lesions (b, d). (h) b-catenin dysregulation leads to an accumulation in the cytoplasm (arrow) but not into the nuclei in
adenocarcinoma and squamous cell carcinoma. Nuclear counterstain in all figures is with Harris hematoxylin. Original magnifications:
 120 (b–h); 300 (a, inset c, inset d, inset h). BrE: Bronchiolar epithelium.
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carcinoma studied expressed very low levels of
ZO-1 expression (figure not shown).
We next studied the EMT using N-cadherin and
vimentin as mesenchymal phenotypic markers
(Figures 6b and 7). We found N-cadherin-expressing
cells in a patchy appearance in nine of 28 adeno-
carcinomas (Figure 6b) and in three of nine
squamous cell carcinomas. We did not find any
correlation between N-cadherin expression and the
degree of fibrosis in adenocarcinomas. In the
squamous cell carcinoma where N-cadherin expres-
sion was found, it was only present in the cords of
infiltrating cells but not in the fully squamous
differentiated area.
Vimentin was not expressed either in hyperplastic
bronchioloalveolar epithelium or in adenomatoid
lesions. Aberrant expression was only found in foci
of cells present in 11 of 28 adenocarcinomas
studied. The vimentin-positive foci were more
commonly observed in fibrotic adenocarcinomas
(7/8) than in the nonfibrotic adenocarcinomas (4/
20), and this difference was statistically significant
(Po0.01, Fisher’s exact test).
To confirm the epithelial phenotype of the tumor
cells that expressed mesenchymal markers, we used
antibodies against epithelial markers like cytoker-
atins and E-cadherin. Coexpression of epithelial and
mesenchymal markers was analyzed by immunos-
taining serial and face-reverse sections of the
tumoral lesions with the relevant markers. Figures
7a–b and c–e are examples of the patterns of
coexpression of epithelial and mesenchymal mar-
kers observed. We found that E-cadherin and
cytokeratins co-expressed with vimentin in 100%
of tumoral positive foci demonstrating that the
epithelial phenotype of the tumoral lesions is
preserved even when traits of mesenchymal pheno-
type are found (Figure 7a–b, c–d). Also, N-cadherin
Figure 5 Statistical analysis of the expression of b-catenin. Semiquantitative analysis of the expression of b-catenin in the normal
epithelia and in the different types of lesions. Normal bronchiole adjacent to the lesion was used as internal positive control of staining
efficiency and as an internal standard for quantitation. Normal cells: normal bronchiole (B), normal type II pneumocytes (TII Pn);
hyperplastic lesions: bronchiolar hyperplasia (BH) and type II pneumocyte hyperplasia (TII PnH); preneoplastic lesions: adenomatoid
lesions (AL); and tumors: adenocarcinoma (AC) and squamous cell carcinoma (SCC). A Kruskal–Wallis test was applied and the post hoc
pairwise comparisons were calculated using a Mann–Whitney U-test with the Bonferroni adjustment.
Figure 6 Immunohistochemistry of ZO-1 and N-cadherin in silica-induced rat lung carcinogenesis. (a) Loss of expression of ZO-1 (arrow)
in adenocarcinoma compared to normal bronchiole (inset). (b) De novo expression of N-cadherin (arrowhead) in adenocarcinoma.
Counterstaining by Harris hematoxylin. Original magnifications:  60 (a); 120 (b);  300 (inset a).
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co-expressed with both cytokeratin and vimentin in
some tumoral areas (Figure 7e). In the squamous cell
carcinomas, vimentin-expressing foci were observed
in seven of nine tumors studied. Again, cytokeratins
and E-cadherin coexpressed with vimentin in these
tumors. As shown with N-cadherin, vimentin
expression was observed mostly in the irregular
cords infiltrating the surrounding connective tissue
of the squamous cell carcinoma (Figure not shown).
Discussion
In this study we have shown the alteration of
adhesion molecules and the EMT in a rat model of
lung carcinogenesis. In this model, we have found a
progressive loss of adherens junctions components
such as E-cadherin and a- and b-catenins, and
perturbation of epithelial polarity substantiated by
loss of tight junction protein ZO-1. Acquisition of
the mesenchymal phenotype was evident by coex-
pression of vimentin and cytokeratins and de novo
expression of N-cadherin and vimentin in epithelial
tumoral cells.
The present model, representing multistep lung
carcinogenesis,20–22 offers several advantages over
genetically modified models, such as the slow
development of lesions with a progressive transition
from normal to preneoplastic and to well-character-
ized tumors, including adenocarcinomas and squa-
mous cell carcinomas. Another relevant feature of
this model is the intimate link between chronic
inflammation and carcinogenesis, similar to human
lung cancer.29–31 The heterotypic interactions taking
place between epithelial and immune cells have
been shown to play an important role in tumor
initiation, maintenance and development.32
Another interesting finding in this model was the
appearance of the EMT, a common signature in
many types of cancer. Although the spatiotemporal
development of EMT in human tumors is not
completely characterized in vivo, several reports
suggest that EMT represents a potential mechanism
of carcinoma progression. We have found evidence
Figure 7 EMT in rat lung carcinogenesis. (a,b) Coexpression of E-cadherin (a) with vimentin (b) in EMT areas (arrow) but not in areas of
well-differentiated adenocarcinoma (arrowhead), where only E-cadherin expression is observed. (c–e) Immunohistochemical study of
vimentin expression (c), cytokeratins (d) and N-cadherin (e) in serial sections of adenocarcinoma. Several patterns of coexpression are
observed in these images: arrowhead points to areas of simultaneous expression of vimentin and cytokeratins but not of N-cadherin;
arrow shows concomitant expression of cytokeratins and N-cadherin but not of vimentin; star indicates simultaneous expression of
vimentin, cytokeratins and N-cadherin. Counterstaining by Harris hematoxylin. Original magnifications:  60 (a,b); 120 (c–e).
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of EMT only in tumors but not in preneoplastic
lesions. Thus, this process represents a late stage
after the decrease of cell adhesion components, E-
cadherin/catenin complex, which starts in preneo-
plastic lesions. In human carcinogenesis, only fully
established lung carcinomas have been studied for
E-cadherin/catenin complex alterations.4,33–35 In the
present model, we have been able to study these
molecules in early hyperplastic and preneoplastic
lesions of bronchiolar and alveolar type II cells. We
observed that a- and b-catenin appeared in a
granular cytoplasmic pattern in tumors. Our data
are in partial agreement with the aberrant expres-
sion and localization of b-catenin that has been
reported in a variety of human cancers including
colon,36 liver,37 stomach,38 pancreas,39 bone,40 and
thyroid.41 Reports that have studied the expression
of b-catenin in human lung cancer remain contro-
versial. Some authors, in agreement with the present
observations, reported restricted cytoplasmic locali-
zation and never found b-catenin nuclear transloca-
tion,34,42–45 whereas some other studies show
cytoplasmic and nuclear localization of b-cate-
nin.33,46–48 Although we did not detect b-catenin in
the nucleus, we cannot rule out the possibility that
b-catenin accumulation in the cytoplasm could lead
to the translocation of undetectable levels of the
protein to the nucleus, which could lead to the
activation of target genes.
Several mechanisms have been reported to con-
tribute to the dowregulation of key adhesion
proteins. These include decrease or lack of
E-cadherin/catenin expression by mutations and
deletions in the genes encoding E-cadherin or
catenin, promoter hypermethylation of E-cadherin,
or post-translational modifications.4,6,45,49–51 To look
into the specific possible causes of the downregula-
tion of E-cadherin, we studied the DNA methylation
status of its promoter region in tumors with reduced
expression, since aberrant hypermethylation was
demonstrated to be one of the most important
mechanisms of inactivation of this adhesion
protein in human7 and mouse52 cancer. Our results
revealed that the promoter hypermethylation of
E-cadherin may be an important mechanism for its
repression in our rat model. However, we cannot
discard other potential mechanisms implicated in
E-cadherin repression. For instance, downregula-
tion of E-cadherin during EMT in several human
cancers could also be mediated by Slug and Snail
transcriptional repressors.53–55
In addition to adherens junctions, integrity of
cell–cell contacts depends also on tight junction
proteins. ZO-1, the mammalian homologue of dlg, a
tumor suppressor gene in Drosophila, is a compo-
nent of tight junctions and can interact with
adherens junctions such as a-catenin and other
adaptor proteins. ZO-1 is related to EMT,56 and has
been associated with proliferation56,57 and tumor
formation.56,58 A truncated ZO-1 protein containing
only the Postsynaptic density/Disc large/Zona
occludens-1 (PDZ) domains induced dramatic EMT
in canine kidney cells.56 We observed a marked
reduction of ZO-1 in tumors compared to normal
epithelium, revealing an evident loss of epithelial
polarity in tumors. ZO-1 has been shown to interact
with a variety of transmembrane proteins including
occludins, cingulin, adherens junction components,
and gap junction proteins.56,59–61 This close interac-
tion may explain a hypothetical simultaneous
perturbation of adherens and tight junctions as a
consequence of the same signalling event; however,
when studying serial sections, we did not observe a
parallel decrease of E-cadherin and reduction/
absence of ZO-1. Altered integrity of these proteins
could induce aberrant signals leading to uncon-
trolled proliferation.57
Neoexpression of mesenchymal markers repre-
sents the hallmark of EMT. Both vimentin and N-
cadherin, which are not normally expressed in
epithelial cells, coexpressed with cytokeratins in
neoplastic cells of tumors present in the silica-
induced lung cancer rat model. De novo expression
of N-cadherin has also been shown in other human
cancers and its expression was correlated with
acquisition of a more invasive phenotype. For
instance, a switch towards N-cadherin expression
was reported in human prostate cancer and its
expression in prostate cell lines correlates with a
more aggressive invasive phenotype.9 Inhibition of
N-cadherin expression in a squamous carcinoma-
derived cell line expressing N-cadherin-induced
epithelial morphology and E-cadherin expression.62
On the other hand, induced expression of N-
cadherin in human breast cancer cells resulted in
increased motility and invasion.63 Similar results
were found in breast cancer cell lines where
expression of N-cadherin correlated with motility,
invasion and metastasis even in the presence of E-
cadherin expression.64 We found N-cadherin expres-
sion restricted to isolated conspicuous patchy areas
within tumoral masses in adenocarcinomas and
squamous carcinomas. The available in vitro data
on N-cadherin overexpression suggest that the N-
cadherin-positive cells found in our model may
have a more aggressive phenotype than the rest of
neoplastic cells. N-cadherin has been also proposed
as a factor that promotes interaction with stromal
cells.64 Indeed, N-cadherin was expressed by ade-
nocarcinomas and by the cords of infiltrating
tumoral cells in squamous cell carcinomas. This
finding is consistent with its potential role mediat-
ing the interaction between tumor and stroma
required for neoplastic cell migration. Similar to
N-cadherin, we found foci of vimentin expression in
many adenocarcinomas and squamous cell carcino-
mas. In adenocarcinomas, fibrotic areas presented
more positive foci than nonfibrotic areas. Cords of
tumoral infiltrating cells were totally positive for
vimentin. The finding of vimentin-positive tumoral
cells mainly in fibrotic areas is consistent with other
reports that correlate tumor fibrosis with EMT. In
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fact, acquisition of a mesenchymal phenotype is
associated with expression of mesenchymal markers
and with abundant deposition of extracellular
matrix. Similar observations were reported in other
models, like progressive renal fibrosis, where the
presence of vimentin-positive epithelial cells corre-
lated with increased degree of fibrotic tissue.65,66
E-cadherin downregulation and decreased or mis-
localized a- and b-catenins represent early events in
this model, which are already evident in preneo-
plastic lesions. The loss of adherens and tight
junction components may initiate a cascade of
intracellular signals leading to N-cadherin upregu-
lation and coexpression of mesenchymal markers.
This phenotypic switch that represents the hallmark
of EMTwas only observed in tumors, in late stages of
multistep carcinogenesis (Figure 8).
Since the EMT is a common signature to many
types of cancer, the signals driving this key event are
currently under investigation.67,68 A number of
studies have shown that EMT occurs in response
to growth factors.69–73 The role of growth factors
and cytokines in the pathogenesis of silica-induced
lung carcinogenesis has been the object of earlier
studies.20–22,74–77 It was shown that hyperplastic type
II cells present in this model are sites of active
production and secretion of TGF-b1.21,76 In rat
alveolar cells in culture, silica treatment induced a
dramatic secretion of TGF-b1.77 These data raise the
possibility that TGF-b, and other growth factors
secreted by the preneoplastic and neoplastic cells,
could play a role in inducing the EMT observed in
our model.
In conclusion, we have shown that an animal
model for multistep lung carcinogenesis mimics the
EMT observed in clinical samples and in vitro
models. This animal model represents a useful tool
to assess the expression of other components
involved in this transition and to understand the
molecular events driving this process. Future stu-
dies, through the systematic analysis of differen-
tially expressed genes, will address the genetic and
epigenetic regulation of gene expression and the
cell-to-cell and cell–matrix interactions involved in
the EMT.
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